Morgan Stanley analyst Terence Flynn lowered the firm’s price target on United Therapeutics (UTHR) to $516 from $519 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- United Therapeutics reports Q1 EPS $5.82, consensus $6.86
- Morning Movers: Corning skyrockets following Nvidia pact
- United Therapeutics’ Earnings Call Signals Next Growth Phase
- Notable companies reporting before tomorrow’s open